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Introduction: The gross majority of extramedullary plasmacytomas arise in the lymphatic tissue of the upper
respiratory tract. On average, one third of patients with a solid plasmacytoma will develop multiple myeloma,
resulting in a worse clinical outcome. We describe a case of rapid recurrent extramedullary plasmacytomas in the
background of an asymptomatic multiple myeloma.
Case presentation: A 71-year-old, white Caucasian woman presented with three extramedullary plasmacytomas
occurring within a short time period. The third plasmacytoma was accompanied by progressive cervical pain and
swallow dysfunction. Additional immunostaining test results were negative for CD56 and showed high MIB-1
expression in the extramedullary plasmacytoma and low MIB-1 expression in the bone marrow. A conventional
swallow X-ray did not show any obstruction, however a magnetic resonance imaging scan of her cervical backbone
revealed an extramedullary plasmacytoma, threatening her spinal cord. A short course of radiation therapy alleviated
her pain and during almost a two-year follow-up period, the multiple myeloma remained asymptomatic, despite the
rise in immunoglobulin A lambda levels. After the appearance of the third plasmacytoma, systemic chemotherapy
was started to prevent the development of a fourth plasmacytoma, despite the asymptomatic character of the
multiple myeloma.
Conclusions: In this case report we describe the rapid appearance of extramedullary plasmacytomas in the
background of an asymptomatic multiple myeloma. An immunohistochemical analysis was negative for CD56
and showed high MIB-1 expression in the extramedullary plasmacytoma and low MIB-1 expression in the bone
marrow, contributing to the potential underlying pathophysiology of the recurrent extramedullary plasmacytomas
and their genetic changes. Systemic chemotherapy was started and no fourth extramedullary plasmacytoma has
developed since.
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Multiple myeloma is a neoplasm of proliferating mono-
clonal B cells which are terminally differentiated (plasma
cells). The process of the development of mature B cells
into a malignant plasma cell population is a multi-step
process [1]. During the initial malignant transformation,
the plasma cells resides in the bone marrow. How-
ever, later on in the transformation, extramedullary
manifestations can occur such as the development of
plasmacytomas [2].* Correspondence: saskia.schols@mumc.nl
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unless otherwise stated.Plasmacytomas are included in the World Health
Organization (WHO) classification and are associated
with the production of a monoclonal immunoglobulin
or light chains [3]. In the absence of systemic involve-
ment, the WHO describes two types of plasmacytomas:
solitary plasmacytoma of the bone and extramedullary
plasmacytoma (EMP). More than 80% of EMPs arise in
the rich lymphatic tissue of the upper respiratory tract.
In 17 to 33% of plasmacytomas, the extramedullary dis-
ease will develop into multiple myeloma.
The mean age of developing extramedullary plasmacy-
toma is 55 years, with a predominance for the female
sex. Solitary EMPs are highly radiosensitive and many
case reports have shown good disease control with ex-
ternal beam radiation therapy, with a 10-year overallral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Biochemical parameters at diagnosis and after
one year at the time of recurrence of her third
extramedullary plasmacytoma
Parameter May 2011 June 2012
Hemoglobin (7.5-10mmol/L) 8.9 7.4
Leucocytes (4–10 × 109/L) 5.7 10.2
Creatinine (49-90umol/L) 74 62
Calcium (2.15-2.55mmol/L) 2.24 2.16
ß2-microglobulin (800-2200mg/L) 2400 2450
Total IgA lambda g/L 6.0 17.3
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current EMPs in the upper part of the body in a woman
with an asymptomatic multiple myeloma without signs
of organ involvement.
Case presentation
A 71-year-old white Caucasian woman was diagnosed
with an immunoglobulin A (IgA) lambda multiple mye-
loma stage I in June 2011. At this time, she presented
to the outward clinic of the Máxima Medical Centre
Veldhoven with a painless soft tissue swelling near her
right sternoclavicular joint. An immunocytological examin-
ation of this swelling showed an IgA lambda monoclonal
plasma cell population analogical to an EMP. Further im-
munostaining tests were negative for CD56, and revealed a
high MIB-1 index.
Additional blood tests revealed normal kidney func-
tion, no anaemia, a normal calcium level, no quantifiable
M-protein and no lytic bone lesions. A bone marrow
biopsy showed a monoclonal IgA lambda plasma cell
population (10 to 20% presence) and she was treated
with local radiation therapy.
One year later, she returned to the outward clinic with
a swelling on her chest which was increasing in size. A
magnetic resonance imaging (MRI) scan of her thorax
showed a soft tissue pre-sternal swelling, suspected to be
an EMP. As with the first EMP, she was treated with
radiation therapy.
Two months after the development of her second
EMP, she noticed some difficulty with swallowing and
she experienced localised cervical pain. In the next few
weeks, her ability to swallow deteriorated and eventually
she could no longer eat solid food and started to lose
weight. Her cervical pain increased with movement of
her neck and was accompanied by tingling in both arms
and hands. There was no loss of muscle power.
At her presentation to the outpatient service, she was
very anxious and was experiencing fear of suffocating.
She had an extensive list of pain medication, however
her pain was able to be brought under control. Her add-
itional physical examination showed tense cervical mus-
cles, no palpable swelling of her throat and no evidence
of neurological loss. Her blood examination showed a
hemoglobin level of 7.4mmol/L, a creatinine level of
62umol/L, a calcium level of 2.24mmol/L and an in-
creased IgA lambda of 17.3g/L (compared to 6.0g/L at
her diagnosis in 2011, Table 1). A swallow X-ray with
oral contrast did not show any dysfunction or limitations
in her intrapharyngeal lumen (Figure 1). In addition, an
MRI scan of her cervical backbone was performed,
which revealed a solid tumor of soft tissue at paraverteb-
ral level C2-3 with extension to the spinal cord, which
we suspected to be a plasmacytoma (Figure 2). Her bone
marrow biopsy showed an increase in her monoclonalplasma cell population to 34%. Additional immunostain-
ing tests showed a low MIB-1 index and were negative
for CD56.
In view of the potential threat to her spinal cord, local-
ised radiotherapy was started directly. This consisted of
five sequences at 20Gy. After only two radiation ses-
sions, the pain was relieved and she could swallow liquid
food again and needed no additional pain medication.
Because of the rapid recurrence of three plasmacytomas
in one year, systemic chemotherapy was started in the
form of melphalan, prednisone and thalidomide. After
three cycles of chemotherapy she continued to have a
satisfactory response (Figure 3).
Discussion
The presence of an EMP at the time of diagnosing mul-
tiple myeloma is associated with a poor outcome com-
pared to cases in which plasmacytomas develop during
the course of the disease (median overall survival 28 ver-
sus 68 months) [2]. In a recent study by Varettoni et al.,
the incidence and outcome of EMP was described in a
large cohort study of patients with multiple myeloma
[5], comparing three distinct time periods; 1971 to 1993,
1994 to 1999 and 2000 to 2007. Of the 1,003 patients
who were studied, only 13% had EMPs (7% at the time
of diagnosis and 6% during the follow-up period). Inter-
estingly, the incidence of EMP seems to have increased
over recent years. One explanation for this could be the
more sensitive imaging techniques that are used today,
such as MRI scanning. Concerning our case report, a
conventional swallow X-ray did not reveal the cause of
the swallow dysfunction. However, her MRI scan showed
the EMP in the lower part of her pharynx.
Another important factor for the increased incidence
in EMPs is prolonged survival due to new treatment
strategies, such as the combination of radiotherapy with
novel agents like proteasome inhibitors and immune
modulators [6,7]. EMPs are highly radiosensitive; more
than 80% of patients can achieve local control [8]. How-
ever, in the presence of rapid recurrence of plasmacy-
toma with evidence of an increase in the monoclonal
Figure 1 Swallow X-ray with oral contrast. No marked obstruction was visible during the swallow act.
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after radiotherapy may be considered [9]. The precise
role of new therapeutic agents in the management of
plasmacytomas has yet to be determined.
EMPs usually arise in the submucosa of the upper re-
spiratory tract and the gastro-intestinal tract, as in the
last plasmacytoma of this case report. However, they can
arise in any part of the body [9]. For choosing the right
treatment option (local radiotherapy versus systemic
chemotherapy), systemic involvement of multiple mye-
loma must be ruled out. There are several criteria that
must be confirmed in order to diagnose the presence of
an EMP without symptomatic multiple myeloma [10],
which are as follows: normal levels of hemoglobin, cal-
cium and kidney function, an absence of lytic bone le-
sions, a low serum M-protein level and a tissue biopsy
showing a monoclonal plasma cell population.Concerning our patient, there was no evidence of an-
aemia, hypercalcemia, kidney dysfunction or lytic bone
lesions. Her M-protein level did rise from 6.0 to 17.3g/L
(Figure 4). Although this is nearly a threefold increase,
it was not accompanied by any evidence of organ
involvement.
The pathophysiological mechanism for EMPs is not
yet fully determined. One suggestion is that multiple
myeloma cells and the bone marrow microenvironment
tightly interact with each other. This is mediated by
multiple soluble factors and adhesion molecules. Integ-
rins acting as receptors on stromal cells and the extra-
cellular matrix play an important role in the homing of
multiple myeloma cells in the bone marrow [11].
Changes in these adhesion molecules and integrins can
lead to the migration of multiple myeloma cells to the
bloodstream (plasma cell escape), and finally to the
CA B
Figure 2 Cervical backbone magnetic resonance images showing a solid tumor of soft tissue extending from the spinal cord (arrows).
A and B represent sagittal images, C represents the axial image.
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addition, for plasma cells to migrate outside of the bone
marrow, genetic changes must occur which give these
migrating plasma cells their aggressive nature. Recent
studies have investigated the expression of several
(glyco)proteins in multiple myeloma [12-14]. Mutations
in genes encoding these proteins, like p53, play a major
role in the aggressive character of the disease. p53 is a
nuclear protein which provides genomic stability by
regulating the cell cycle. Another protein, CD56 is usu-
ally present as a membrane glycoprotein on natural
killer cells and T cells and is involved in cell adhesion
and migration. CD56 is expressed in more than 70% of
plasma cells in multiple myeloma, however it is not
expressed in normal plasma cells. There is evidence
that CD56 is downregulated in extramedullary multiple
myeloma.
A recent study by Sheth et al. investigated the associ-
ation of p53, CD56 and MIB-1 expression in intramedul-
lary and extramedullary biopsies of multiple myelomapatients with progression to extramedullary myeloma
[15]. The results showed that in extramedullary multiple
myeloma biopsies, nuclear p53 immunoreactivity and
the MIB-1 staining index were significantly higher than
in intramedullary and EMP biopsies. CD56 staining was
expressed in a low number of all biopsies. To conclude,
the study demonstrated an association of high p53 im-
munoreactivity in extramedullary multiple myeloma and
an increased cell proliferation (MIB-1 staining), probably
due to progression of the disease. Concerning our pa-
tient, there was a high expression of MIB-1 and negative
CD56 level in the EMP. On the contrary, her bone mar-
row biopsy showed a low MIB-1 expression. Unfortu-
nately we have no information about the nuclear p53
level. However the high MIB-1 staining in the EMP
points to the aggressive character of the disease. Further-
more, downregulation of CD56, as in both our biopsies, is
associated with more aggressive disease progression by the
facilitated extravasation of myeloma cells [13,15]. More
studies are needed to determine the exact association
Figure 3 Cervical backbone magnetic resonance image after irradiation therapy and adjunctive chemotherapy. Her spinal cord
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Figure 4 Level of immunoglobulin A (IgA) lambda during the follow-up period after diagnosing multiple myeloma and the first
extramedullary plasmacytoma (EMP). Additionally, the development of the three plasmacytomas are shown in association with the time
of complaints.
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sion of multiple myeloma and EMP.
In conclusion, the increased availability of performing
immunohistochemical staining allows the physician to
detect more aggressive EMPs, and thus to start systemic
chemotherapy sooner. For future management this will
implicate more targeted therapies that interfere with the
cell proliferation function of p53 and MIB-1 expression.
Conclusions
In this report, we present a case of aggressive develop-
ment of EMPs in the background of an asymptomatic
multiple myeloma. Despite an increase in the IgA
lambda level, no organ involvement occurred. Few stud-
ies have been performed considering the implication of
genetic changes such as nuclear accumulation of p53
and MIB-1 expression on the aggressive nature of mul-
tiple myeloma and EMPs. There seems to be an import-
ant association between accumulation of p53, a high
MIB-1 expression and downregulation of CD56 with the
progression of multiple myeloma and the presence of
plasmacytomas. In our patient, the first EMP exposed a
high level of MIB-1 and was negative for CD56, with
concomitant low MIB-1 expression and no evidence of
CD56 in the bone marrow. These genetic changes
pointed to the aggressive nature of the plasmacytoma
and justify the start of systemic chemotherapy after the
appearance of the third plasmacytoma.
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